Microglia-independent rAAV-induced inflammation causes persistent ocular immune dysregulation rescued by S1P receptor modulation.

Abstract

Inflammation elicited by rAAV vectors continues to present a critical challenge for the long-term efficacy and safety of gene therapy in the eye. Preclinical models of gene therapy-associated uveitis (GTAU) show that despite the resolution of early acute inflammatory response, persistent subclinical inflammation remains. Here, we employ the GTAU model in Cx3cr1:R26-tdTomatomice to reveal that intravitreal rAAV2 administration elicits sustained microglial dysregulation and retention of CD3T cells extending to 50 days post-injection. Deploying pharmacologic and genetic approaches, we define the absolute requirement for microglia and T cells to mediate rAAV2-induced inflammation. Targeted depletion confirmed that microglia-independent mechanisms initiate GTAU, while elimination of lymphocytes prevented both inflammation and microglial activation. Systematic evaluation of therapeutic strategies reveals identified inhibition of T cell recruitment via sphingosine-1-phosphate receptor modulation, but not B cell depletion, as an effective steroid-sparing strategy to prevent both acute and long-term subclinical inflammation. Collectively, our findings challenge the paradigm of microglia-driven ocular inflammation and support the utility of targeted T cell immunomodulation strategies to control GTAU and maintain long-term ocular homeostasis.